Zurich Cantonal Bank
ARQT icon

Zurich Cantonal Bank’s Arcutis Biotherapeutics ARQT Stock Holding History

Zurich Cantonal Bank’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
42,648
+517
+1% +$12K ﹤0.01% 1489
2026
Q1 		$993K Buy
42,131
+5,072
+14% +$129K ﹤0.01% 1438
2025
Q4 		$1.08M Sell
37,059
-39,122
-51% -$1M ﹤0.01% 1297
2025
Q3 		$1.44M Buy
76,181
+46,616
+158% +$735K ﹤0.01% 1089
2025
Q2 		$415K Sell
29,565
-132
-0.4% -$1.85K ﹤0.01% 1770
2025
Q1 		$464K Buy
29,697
+917
+3% +$12.9K ﹤0.01% 1642
2024
Q4 		$401K Buy
28,780
+10,018
+53% +$110K ﹤0.01% 1766
2024
Q3 		$174K Hold
18,762
– – ﹤0.01% 2183
2024
Q2 		$174K Buy
+18,762
New +$170K ﹤0.01% 2106
2023
Q4 		– Sell
-6,060
Closed -$32.2K – 2731
2023
Q3 		$32.2K Sell
6,060
-1
-0% -$9 ﹤0.01% 2667
2023
Q2 		$57.8K Hold
6,061
– – ﹤0.01% 2565
2023
Q1 		$66.7K Sell
6,061
-965
-14% -$14K ﹤0.01% 2501
2022
Q4 		$104K Buy
7,026
+1,134
+19% +$19.8K ﹤0.01% 2241
2022
Q3 		$113K Buy
5,892
+4,530
+333% +$103K ﹤0.01% 2116
2022
Q2 		$29K Sell
1,362
-132
-9% -$2.71K ﹤0.01% 2730
2022
Q1 		$29K Buy
+1,494
New +$25.3K ﹤0.01% 2612

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Zurich Cantonal Bank's ARQT Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Arcutis Biotherapeutics (ARQT) stake by 1.2% in Q2 2026, buying an estimated $12K and bringing the position to 42,648 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Zurich Cantonal Bank first reported a position in ARQT in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.44M in Q3 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Zurich Cantonal Bank held 42,648 shares of Arcutis Biotherapeutics worth $1.12M as of Q2 2026.
  • Zurich Cantonal Bank bought 517 Arcutis Biotherapeutics shares in Q2 2026, an estimated $12K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1489 holding.
  • Zurich Cantonal Bank first reported a position in Arcutis Biotherapeutics in Q1 2022 and has held it in 16 quarters since.
  • Zurich Cantonal Bank's Arcutis Biotherapeutics position peaked at $1.44M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.